Overview

A Study to Induce Tolerance in de Novo Renal Transplantation

Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if TCD601with donor bone marrow and conditioning using fludarabine and cyclophosphamide can induce allogeneic tolerance in de novo living donor renal transplant recipients
Phase:
Phase 2
Details
Lead Sponsor:
ITB-Med LLC
Treatments:
Cyclophosphamide
Fludarabine
Sirolimus
Tacrolimus